28.03.2016 07:49:50
|
Dr. Reddy's Granted U.S. Rights For XenoPort's Clinical-stage XP23829
(RTTNews) - Dr. Reddy's Laboratories (RDY) and XenoPort, Inc. (XNPT) announced a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity, XP23829. XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials. XenoPort will also be eligible to receive up to $190 million upon the achievement by Dr. Reddy's Laboratories of certain regulatory milestones. XenoPort will be eligible to receive up to $250 million upon the achievement of commercial milestones, and up to mid-teens royalty payments based on potential net sales of XP23829 in the U.S.
XP23829 is an investigational drug discovered by XenoPort. In September 2015, XenoPort announced results of a Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis.
Dr. Reddy's plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu XenoPort Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu XenoPort Inc.mehr Analysen
Aktien in diesem Artikel
Dr. Reddy's Laboratories Ltd. (Spons. ADRS) | 12,20 | -1,61% |
|